Dr. Jared A. Jaffe, DO
Nephrology (Kidney) (Nephrology Physician)
- Medicare participating
At a glance
- Years since graduation
- 27
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 1,050
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Nephrology Physician primary
FL license 0S9389
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Boca Raton Regional Hospital Boca Raton, FL
- Bethesda Hospital East Boynton Beach, FL
- Delray Medical Center Delray Beach, FL
- West Boca Medical Center Boca Raton, FL
Medical groups
- Boca Nephrology PA (4 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 1,050
- Services billed
- 9,117
- Patients’ average age
- 81
| Service | Times | Patients |
|---|---|---|
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 2,050 | 339 |
| Established patient office or other outpatient visit, 30-39 minutes | 1,218 | 628 |
| Dialysis services, per day, less than full month service (20 years or older) | 1,184 | 33 |
| Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional | 763 | 424 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 682 | 400 |
| Automated urinalysis test | 671 | 401 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 367 | 305 |
| Dialysis services, 4 or more physician visits per month (20 years or older) | 191 | 34 |
| New patient office or other outpatient visit, 60-74 minutes | 125 | 125 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 113 | 57 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 27 companies reported 136 payments worth $3,425 in total to this clinician.
| Calliditas Therapeutics US Inc. | $348 |
|---|---|
| Opko Pharmaceuticals, LLC | $284 |
| Bayer HealthCare Pharmaceuticals Inc. | $244 |
| Otsuka America Pharmaceutical, Inc. | $238 |
| Amgen Inc. | $231 |
| Novartis Pharmaceuticals Corporation | $212 |
| Alexion Pharmaceuticals, Inc. | $182 |
| Travere Therapeutics, Inc. | $177 |
| Food and Beverage | $3,425 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $191,038 in research payments for these studies, mostly to the institutions running them.
- Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)
Csl Behring · Recruiting · NCT05485961
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.